Manufacturing Chemist
  • Home
  • Categories
    • Ingredients
    • Analysis
    • Manufacturing
    • Finance
    • Company News
    • Regulatory
    • Drug Delivery
    • Research & Development
    • Sustainability
  • Pharma 5.0
  • Events
  • Directory
  • Search
    • Close search
  • Subscribe
  • Login
    • Password
      Password
      Forgot password? Close login form
  • Home
  • Company News

Company News

High Force Research makes boardroom changes following retirement of Managing Director High Force Research makes boardroom changes following retirement of Managing Director High Force Research makes boardroom changes following retirement of Managing Director Bob Redfern co-founded the firm in 1988 PlaqueTec appoints Dr Tim Brears as CEO PlaqueTec appoints Dr Tim Brears as CEO PlaqueTec appoints Dr Tim Brears as CEO Cambridge firm is pioneering a biomarker-based approach to understanding coronary artery disease EMD Serono appoints Scott Filosi as Senior Vice President of Managed Markets EMD Serono appoints Scott Filosi as Senior Vice President of Managed Markets EMD Serono appoints Scott Filosi as Senior Vice President of Managed Markets Filosi brings 20 years of market access experience to the EMD Serono leadership team David Kaysen named President and CEO of Sun BioPharma David Kaysen named President and CEO of Sun BioPharma He brings more than 25 years of healthcare, commercial and public company experience to the firm Nuevolution welcomes two new faces Nuevolution welcomes two new faces Jeanette Wood joins the board as scientific advisor, while Henrik Simonsen joins the firm as Chief Financial Officer Merck reorganises Healthcare management team Merck reorganises Healthcare management team Merck reorganises Healthcare management team Forms a new Healthcare Executive Committee to accelerate delivery of pipeline in immuno-oncology, immunology and oncology Ian Tomlinson becomes Independent Chairman of Stevenage Bioscience Catalyst Board Ian Tomlinson becomes Independent Chairman of Stevenage Bioscience Catalyst Board Ian Tomlinson becomes Independent Chairman of Stevenage Bioscience Catalyst Board Will guide open innovation campus in a phase of rapid development InMed appoints Paul Brennan as President and CEO InMed appoints Paul Brennan as President and CEO He succeeds Craig Schneider who remains on the board of directors New Chief Medical Officer at Endo New Chief Medical Officer at Endo Craig Paterson takes responsibility for global clinical development strategies at the company Extract Technology appoints two engineering apprentices Extract Technology appoints two engineering apprentices Extract Technology appoints two engineering apprentices Company is committed to the apprenticeship model as a way of introducing young adults into engineering Michael Meyers joins Syndax Pharmaceuticals as SVP and Chief Development Officer Michael Meyers joins Syndax Pharmaceuticals as SVP and Chief Development Officer Brings significant experience in oncology drug development to expanding clinical programme Vanda Pharmaceuticals hires European General Manager Vanda Pharmaceuticals hires European General Manager Gian Piero Reverberi has more than 20 years of pharma industry experience I Holland appoints new Sales and Marketing Director I Holland appoints new Sales and Marketing Director I Holland appoints new Sales and Marketing Director Javier Raposo takes responsibility for business development Dr John Hutchison joins Autifony Therapeutics as Chief Medical Officer Dr John Hutchison joins Autifony Therapeutics as Chief Medical Officer Dr John Hutchison joins Autifony Therapeutics as Chief Medical Officer Dr Peter Harris will retire at the end of September Kloeckner Pentaplast appoints Wayne M Hewett as CEO Kloeckner Pentaplast appoints Wayne M Hewett as CEO He joins the firm from Arysta LifeScience AmpliPhi Biosciences appoints Alexander Gaidamaka as Vice President of CMC AmpliPhi Biosciences appoints Alexander Gaidamaka as Vice President of CMC Will oversee the compliant manufacture and quality assurance of phage-based therapeutics
  • Previous
  • 1
  • …
  • 105
  • 106
  • 107
  • 108 (current)
  • 109
  • 110
  • 111
  • …
  • 213
  • Next

Trending Articles

  1. Lonza appoints Hans Trees as Global Head of Communications Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
  2. MHRA scientific leader recognised in 2026 King's Birthday Honours Dr Nicola Rose receives OBE for services to science and public health
  3. Servomex appoints new Global Sales Director Servomex, international expert in gas analysis, has appointed David Jones as Global Sales Director to lead and strengthen its worldwide commercial strategy. Based in the UK head office, David brings more than three decades of experience in management and commercial leadership, along with a strong vision for Servomex at a time of rapid growth in semiconductor manufacturing, tightening emissions regulations, and rising demand for precision gas analysis
  4. Alfa Laval appoints new managing director to drive strategic growth Alessandro Bracco will lead Alfa Laval UK & Ireland as the company targets growth opportunities across key sectors, including pharmaceutical
  5. Entact Bio appoints John G. Houston, Ph.D., to its Board of Directors A veteran biopharma innovator who helped advance the first FDA-approved PROTAC drug, Dr. Houston will strengthen Entact's leadership in induced-proximity therapeutics

Upcoming event

CPhI Milan

6–8 October 2026 | Exhibition | Fiera Milano, Italy
See all

Become a Subscriber

Subscribe now Already a subscriber? Sign in here. Find out more

Get our newsletter

Follow us

  • LinkedIn
  • About Manufacturing Chemist
  • About HPCi Media
  • Newsletter sign up
  • Contact Us
  • Advertise
  • Terms and Conditions
  • Privacy
© HPCi Media Limited | Registered in England No. 06716035 | VAT GB 939828072 | a Claverley Group company Registered office address:
One Anchorage Avenue,
Shrewsbury Business Park,
Shrewsbury,
SY2 6FG, UK.